Mediford supports drug development in Japan through laboratory services in bioanalysis, biomarkers, pathology, and nonclinical safety. Its teams use technologies such as LC-MS, ligand-binding assays, flow cytometry, genomic analysis, and tissue-based methods to measure drug exposure and biological response. Work performed within established quality systems can support toxicology studies, clinical trials, and regulatory submissions for both domestic and global development programs.
Mediford Corporation
Mediford Corporation is a premier Japanese contract research organization (CRO) specializing in preclinical and clinical bioanalysis, safety evaluation, and biomarker testing. Operating under strict GLP guidelines, Mediford provides the pharmaceutical industry with high-quality analytical services, pharmacokinetic evaluations, and regulatory-grade data to support global drug submissions.
The Latest Insights & Innovations from
Mediford Corporation
No items found.
Blog
Precision in PBMC Isolation and Analysis: Driving Next-Gen Therapeutic Solutions
November 14, 2024
Learn more
No items found.
No items found.